All In Biotech

Drug Trial Radar · NCT07834346

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Oct 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Hellenic Institute for the Study of SepsisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII). The primary objective is to evaluate the effect of clarithromycin on the incidence of new infection, including worsening or recurrence of the initial CAP episode, new infections at other sites, and secondary sepsis during the 28-day follow-up period. Secondary objectives are to investigate the impact of clarithromycin on mortality, sepsis response, type of secondary infection, time to antimicrobial escalation, hospital readmission, quality of life, cost-effectiveness, and biomarkers of sepsis-induced immunoparalysis. Researchers will compare clarithromycin plus standard-of-care antibiotic therapy to placebo plus standard-of-care antibiotic therapy. Participants will: * Receive clarithromycin or placebo, administered orally or intravenously, in addition to standard-of-care antibiotic therapy for up to 7 days. * Be evaluated during treatment and follow-up through Day 28, with additional assessment of mortality, hospital readmission, and health status through Day 90.

Conditions

  • Sepsis

Interventions

  • PlaceboDrug

    There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.

  • clarithromycinDrug

    There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of new infectionTime frame: Day 1 through Day 28.

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • General University Hospital of Patras, Department of Internal Medicine

    Pátrai, Achaea, Greece · Recruiting

  • Evaggelismos Hospital, 1st Department of Internal Medicine

    Athens, Attica, Greece · Recruiting

  • General Hospital of Athens Korgialenio Benakio H.R.C, Intensive Care Unit

    Athens, Attica, Greece · Recruiting

  • General Hospital of Athens Korgialenio Benakio H.R.C., 1st Department of Internal Medicine

    Athens, Attica, Greece · Recruiting

  • General Hospital of Athens G.Gennimatas, 1st Department of Internal Medicine

    Athens, Attica, Greece · Recruiting

  • Thoracic General Hospital of Athens I Sotiria, 3rd University Department of Internal Medicine

    Athens, Attica, Greece · Recruiting

  • Thoracic General Hospital of Athens I Sotiria, 6th Department of Pulmonary Medicine

    Athens, Attica, Greece · Recruiting

  • General Hospital of Athens Alexandra, Ηigh Dependency Unit of Department of Clinical Therapeutics

    Athens, Attica, Greece · Recruiting

  • University General Hospital Attikon-General Hospital of West Attica H Agia Varvara, 2nd Department of Propaedeutic Medicine

    Athens, Attica, Greece · Recruiting

  • University General Hospital Attikon-General Hospital of West Attica H Agia Varvara, 4th Department of Internal Medicine

    Athens, Attica, Greece · Recruiting

  • General Oncological Hospital of Kifisia Agioi Anargyroi, Intensive Care Unit

    Athens, Attica, Greece · Recruiting

  • University General Hospital of Ioannina, 1st Department of Internal Medicine

    Ioannina, Ioannina, Greece · Recruiting

  • University General Hospital of Thessaloniki Ahepa, Intensive Care Unit

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • Ippokratio General Hospital of Thessaloniki, 2nd Propaedeutic Department of Internal Medicine

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • General Hospital of Thessaloniki Papageorgiou, Department of Internal Medicine

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • Geniko Nosokomeio Thessalonikis George Papanikolaou, Intensive Care Unit

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • University General Hospital of Alexandroupolis, 2nd Department of Internal Medicine

    Alexandroupoli, Thrace, Greece · Recruiting

  • General Hospital of Eleusina Thriasio, 1st Department of Internal Medicine

    Elefsina, West Attica, Greece · Recruiting

  • General Hospital of Eleusina Thriasio, 2nd Department of Internal Medicine

    Elefsina, West Attica, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.